As the number of confirmed cases of COVID-19 continues to rise, healthcare researchers around the world are working tirelessly to discover new life-saving innovations in medicine.
Here are some companies and institutions developing new treatment options for COVID-19
| Vaccine | Company name | Type of Vaccine | Phase of study | Study link |
| mRNA1273 (2019-nCoV Vaccine) | Emory University in Atlanta | RNA | Phase I | https://clinicaltrials.gov/ct2/show/NCT04283461 |
| Ad5-nCoV | Cansino Bio | Non replicating viral vector | Phase I | https://www.precisionvaccinations.com/vaccines/ad5-ncov-covid-19-vacci |
| chadox1 ncov19 | University of Oxford | Non replicating viral vector | Phase I/II | https://www.clinicaltrials.gov/ct2/show/NCT04324606 |
| LVSMENP-DC | Shenzhen Geno immune medical institute | lentiviral | Phase I/II | https://clinicaltrials.gov/ct2/show/NCT04276896 |
| BCG vaccines (Bacille Calmette-Guérin) | Murdoch Childrens Research Institute. | Live Attenuated virus | Phase II/III | https://clinicaltrials.gov/ct2/show/NCT04327206 |
| Drug | Company name | Mechanism of action | Phase of study | Study link |
| Sylvant (Siltuximab) | EUSA Pharma | interleukin (IL)-6 inhibitor | Observational study | https://www.clinicaltrials.gov/ct2/show/NCT04322188 |
| Gimsilumab | Roivant | monoclonal antibody targeting GM-CSF | Phase I | https://clinicaltrials.gov/ct2/show/NCT04351243?intr=Gimsilumab&draw=2&rank=1 |
| Losartan | Univ. of Minnesota | ANGIOTENSIN TYPE 1 RECEPTOR inhibitor | Phase II | https://clinicaltrials.gov/ct2/show/NCT04312009 |
| AiRuiKa (camrelizumab) | Southeast Univ China | PD-1 inhibitor | Phase II | https://clinicaltrials.gov/ct2/show/NCT04268537 |
| Fingolimod | First Affiliated Hospital of Fujian Medical University | Sphingosine 1-phosphate receptor modulator | Phase II | https://clinicaltrials.gov/ct2/show/NCT04280588 |
| SNG001 | Synairgen | IFN-beta 1a Sphingosine phosphate receptor modulator | Phase II | https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB |
| Kaletra | AbbVie’s | HIV protease. | Failed trial | https://news.abbvie.com/news/press-releases/abbvie-partnering-with-global-authorities-to-determine-efficacy-hiv-drug-in-treating-covid-19.htm |
| Ganovo + Ritonavir | Ascletis | HCV NS3/4A protease inhibitor. | Phase IV | https://clinicaltrials.gov/ct2/show/NCT04345276? |
| Actemra (Tocilizumab) | Roche | IL-6 receptors inhibitor | Phase III | https://clinicaltrials.gov/ct2/show/NCT04351152?intr=Lenzilumab&draw=2&rank=2 |
| CD24Fc | Oncoimmune | modulate immune responses | Phase III | https://clinicaltrials.gov/ct2/show/NCT04317040?intr=CD24Fc&draw=2&rank=2 |
| Prezcobix | Shanghai Public health clinical centre | HIV protease inhibitor | Phase III | https://clinicaltrials.gov/ct2/show/NCT04252274 |
| Colchine | The Montreal Heart Institute (MHI) Research Centre | Tubulin Disruption | Phase III | https://clinicaltrials.gov/ct2/show/NCT04322682 |
| Kevzara (sarilumab) | Sanofi and Regeneron | IL-6 receptor | Phase 2/3 | https://clinicaltrials.gov/ct2/show/NCT04315298 |
| Hydroxychloroquine | University of Minnesota | ACE2 inhibitor | Phase II/III | https://clinicaltrials.gov/ct2/show/NCT04308668 |
| Avigan | FUJIFILM | RNA polymerase inhibitor | Phase III | https://www.fujifilm.com/jp/en/news/hq/3211 |
| Avastin (Bevacizumab) | Qilu Hospital of Shandong University | VEGF inhibitor | Phase 2/3 | https://clinicaltrials.gov/ct2/show/NCT04275414 |
| Remdesivir | Gilead | Adenosine analouge | Phase III | https://clinicaltrials.gov/ct2/show/NCT04292730?intr=remdesivir&lead=Gilead&draw=2&rank=3 |
| Leronlimab (PRO140) | CytoDyn | CCR5antagonist | Phase 2b/3 | https://clinicaltrials.gov/ct2/show/NCT04347239?intr=Leronlimab&draw=2&rank=3 |
| Aviptadil | NeuroRx | IL-6 inhibitor | Phase II | https://clinicaltrials.gov/ct2/show/NCT04311697 |
| Lenzilumab | Humanigen | Anti GM-CSF | Phase III | https://clinicaltrials.gov/ct2/show/NCT04351152?intr=Lenzilumab&draw=2&rank=2 |
| Mesenchymal stem cells | various institute | Tissue regeneration | Phase I | https://link.springer.com/article/10.1007/s12015-020-09973-w/tables/1 |
